# Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

Study · id `cardio:ct-nct01874431` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01874431](<https://clinicaltrials.gov/study/NCT01874431>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01874431

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 823 participants.

## Technical summary

Registry record NCT01874431. Randomized; quadruple masking; primary purpose treatment. Start 2013-06-12 (actual); primary completion 2014-07-09 (actual). Results posted on 2021-05-04.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 823 participants (enrolled count; ClinicalTrials.gov record NCT01874431, source copy `cardio:ctgov-nct01874431-2021-07-01`, retrieved 2026-10-26)
- Started: 2013-06-12 (actual) (ClinicalTrials.gov record NCT01874431, source copy `cardio:ctgov-nct01874431-2021-07-01`, retrieved 2026-10-26)
- Primary completion: 2014-07-09 (actual) (ClinicalTrials.gov record NCT01874431, source copy `cardio:ctgov-nct01874431-2021-07-01`, retrieved 2026-10-26)
- Completion: 2014-08-07 (actual) (ClinicalTrials.gov record NCT01874431, source copy `cardio:ctgov-nct01874431-2021-07-01`, retrieved 2026-10-26)
- Results first posted: 2021-05-04 (ClinicalTrials.gov record NCT01874431, source copy `cardio:ctgov-nct01874431-2021-07-01`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Bulgaria; Canada; Czechia; Denmark; Finland; France; Germany; Hong Kong SAR China; Hungary; Israel; Italy; Netherlands; Norway; Poland; Portugal; South Africa; South Korea; Spain; Sweden; Taiwan (ClinicalTrials.gov record NCT01874431, source copy `cardio:ctgov-nct01874431-2021-07-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01874431-2021-07-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
- Acronym: ARTS-DN
- Condition: Diabetic Nephropathies
- Intervention (Drug): Finerenone (BAY94-8862)
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial (`cardio:pubmed-26325557`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease (`cardio:pubmed-31583611`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes (`cardio:pubmed-36583355`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f83b151c3dec387fd2c36c94bcf3caa7e4e8e15089f06969bfad688dbc6e3883
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
